Efficacy and Safety of Tezepelumab in Participants With Severe Chronic Rhinosinusitis With Nasal Polyposis

Completed · Phase 3 · Has a placebo group

Conditions studied: Chronic Rhinosinusitis With Nasal Polyps

In brief

A Multicentre, Randomised, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study of Tezepelumab in Participants with Severe Chronic Rhinosinusitis with Nasal Polyposis

Key facts

Study ID

NCT04851964

Run by

AstraZeneca

People needed

416

Starts

2021-04-22

Expected to finish

2024-12-11

Last updated by the study team

2026-01-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants with physician-diagnosed CRSwNP for at least 12 months prior to Visit 1 that have:
• Severity consistent with need for surgery as defined by total NPS ≥ 5 (≥ 2 for each nostril) at screening, as determined by the central reader
• Nasal Congestion Score (NCS) ≥ 2 at Visit 1
• Ongoing documented NP symptoms over > 8 weeks prior to screening such as rhinorrhea and/or reduction/loss of smell
• SNOT-22 total score ≥ 30 at screening (Visit 1)
• Any standard of care for treatment of CRSwNP provided the participant is stable on that treatment for 30 days prior to Visit 1
• Documented treatment of nasal polyposis exacerbation with SCS for at least 3 consecutive days or one IM depo-injectable dose (or contraindications/intolerance to) within the past 12 months prior to Visit 1 but not within the last 3 months prior to Visit 1 and/or any history of NP surgery (or contraindications/intolerance to)

You may not qualify if…

• Any clinically important comorbidities other than asthma (e.g. active lung infection, bronchiectasis, pulmonary fibrosis, cystic fibrosis, primary ciliary dyskinesia, allergic bronchopulmonary mycosis, hypereosinophilic syndromes, etc.) that could confound interpretation of clinical efficacy results.
• Sinus surgery within 6 months of screening visit OR any sinus surgery in the past which changed the lateral wall of the nose making NPS evaluation impossible.
• Positive COVID-19 PCR test (or COVID-19 rapid test) or COVID-19 entry screening questionnaire during the screening visit. Evaluation will be based on on local standard of care as determined by current local guidelines.
• Regular use of decongestants (topical or systematic) at enrolment is not allowed unless used for endoscopic procedure
• Use of immunosuppressive medication (including but not limited to: methotrexate, troleandomycin, cyclosporine, azathioprine, mycophenolate, tacrolimus, gold, penicillamine, sulfasalazine, hydroxychloroquine, systemic corticosteroids or any experimental anti-inflammatory therapy) within 3 months prior to Visit 1 and during the study period. Systemic corticosteroid use is defined as treatment with a burst of systemic corticosteroids for at least 3 consecutive days or a single IM depo-injectable dose of corticosteroids (considered equivalent to a 3-day burst of systemic corticosteroids).
• Receipt of COVID-19 vaccine (regardless of vaccine delivery platform) 28 days prior to date of IP administration at Visit 3 (randomisation visit).

Where it is running

• Research Site — Bakersfield, California, United States
• Research Site — Newport Beach, California, United States
• Research Site — Roseville, California, United States
• Research Site — Walnut Creek, California, United States
• Research Site — Colorado Springs, Colorado, United States
• Research Site — Denver, Colorado, United States
• Research Site — Boca Raton, Florida, United States
• Research Site — Chicago, Illinois, United States
• Research Site — Baltimore, Maryland, United States
• Research Site — White Marsh, Maryland, United States
• Research Site — Boston, Massachusetts, United States
• Research Site — Columbia, Missouri, United States
• Research Site — New York, New York, United States
• Research Site — Winston-Salem, North Carolina, United States
• Research Site — Oklahoma City, Oklahoma, United States
• Research Site — North Charleston, South Carolina, United States
• Research Site — Dallas, Texas, United States
• Research Site — Norfolk, Virginia, United States
• Research Site — Spokane, Washington, United States
• Research Site — Milwaukee, Wisconsin, United States
• Research Site — Vancouver, British Columbia, Canada
• Research Site — Hamilton, Ontario, Canada
• Research Site — London, Ontario, Canada
• Research Site — Montreal, Quebec, Canada
• Research Site — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.